All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
FDA approval of crizotinib for the treatment of pediatric patients and young adults with ALK-positive R/R ALCL
On January 14, 2021, it was announced that the U.S. Food and Drug Administration (FDA) granted the approval of crizotinib for the treatment of pediatric patients and young adults (1 to ≤ 21 years) with anaplastic lymphoma kinase (ALK)-positive, relapsed/refractory (R/R), systemic anaplastic large cell lymphoma (ALCL). The approval was based on the results of the phase I/II ADVL0912 study (NCT00939770).1
Crizotinib1
- An oral small molecule tyrosine kinase inhibitor.
- Approved by the FDA, European Medicines Agency (EMA), and various other regulatory agencies, for the treatment of patients with ALK- or c-ros oncogene 1 (ROS1)-positive metastatic non-small cell lung cancer.
- Previously granted FDA priority review for ALK-positive, R/R systemic ALCL.
ADVL0912 study1,2
- A single arm, open-label, multicenter, study of 121 patients (1 to ≤ 21 years) with R/R solid tumors and ALCL, of which 26 were ALK-positive.
- Primary outcome measures: maximum tolerated dose, recommended phase II dose, toxicities, pharmacokinetics, and pharmacodynamics.
- Secondary outcome measures: overall response, and number of participants with minimum residual disease.
Results1
- The overall response rate for patients who were ALK-positive was 88%.
- Responses were maintained for ≥ 6 months in 39% of patients, and ≥ 12 months in 22% of patients.
- Toxicities were similar to those for patients with non-small cell lung cancer.
- Excluding laboratory abnormalities, the most common adverse events (≥ 35%), were diarrhea, vomiting, nausea, vision disorder, headache, musculoskeletal pain, stomatitis, fatigue, decreased appetite, pyrexia, abdominal pain, cough, and pruritis.
- The most common Grade 4 hematological adverse events included neutropenia (62%), lymphopenia (35%), and thrombocytopenia (19%).
The EMA has also agreed to a pediatric investigational plan for crizotinib in ALK-positive, R/R systemic ALCL, providing hope for a potential European approval.1
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content